Sphere3D Brings Industry’s First Windows Containerization Platform and Enterprise NAS to Microsoft Azure (CSD777PAL)
Event ID: 1032673848
Starts: Thursday, October 15, 2015 9:00 AM
Time zone: (GMT-08:00) Pacific Time (US & Canada)
Duration: 1 hour(s)
Thanks for registering for Sphere3D Brings Industry’s First Windows Containerization Platform and Enterprise NAS to Microsoft Azure.
Sphere 3D stands apart as the provider of Glassware 2.0™, which is the industry’s first and the only Windows containerization technology. Though the industry has been abuzz with the premise that Linux containers are the new and efficient way to deliver application virtualization, it is often missed that these Linux containers do not apply to the majority of Windows based applications that are in production in corporate IT infrastructures around the world.
The Glassware 2.0 Windows containerization platform combined with the SnapCLOUD™, Sphere 3D’s virtual Network Attached Storage (NAS) in the cloud, delivers unmatched simplicity and scalability, resulting in a drastic TCO reduction to companies that are looking to modernize their IT infrastructure for the mobile workforce. These Sphere 3D solutions are built to be hybrid-cloud ready, and are now available on Microsoft Azure. With these new offerings Microsoft Azure and Sphere3D are set to transform the economics of application virtualization and delivery to any device anywhere, and effectively address the requirements of the Hybrid cloud market, which is projected to grow to $84.67 billion by 2019 (source: MarketsandMarkets March 2015 research report on “Hybrid Cloud Market”).
Glassware 2.0™ - A Windows containerization technology that can virtualize 16, 32, and 64-bit Microsoft Windows applications and deliver them with native functionality to most end user devices: Chromebooks, Windows 10 clients, iPads, thin clients, tablets, etc. Glassware 2.0 uses a container-based approach to application virtualization deployed
Exactly. Compelled me to buy 1500 more shares as low as $17.99.
Full disclosure: First buy at $18.60.
OSIR will be one of the first biotechs to recover. That's my new mantra. Now all together.......
Surgeons that are the first to learn new procedures, as a group, tend to be the busiest and most aggressive in their respective locales. Also when word gets out patients will be asking for this new and improved procedure. I won't hazard a guess on numbers of procedures but 2.4 strikes me as very very very conservative. And regarding surgeons behavior I could be considered an expert.
Is this a fly-by or can we expect an extended comedy routine in the Land of Ignore?
Tip: Need to work on your jokes.
I've got a good one for you. Listen up. I bought 4000 shares today average less than $18.50. Good one, eh?
I've been having a field day today...on a constrained budget of course. Slightly embarrassed that I bought a few hundred over $20 recently. What's new!
The dividend sent a message to this shareholder. The message was that product acceptance and accelerated growth are slam dunks.
I have a very long association with this company through thick and thin and believe management to be honest and very competent. And insiders own 50% of the shares...and the float is miniscule.
The message to me was that buying more shares is prudent and that is what I intend to do.
NIce fairy tale.
Sure that the dividend caught the eye of the shorts. Will cost them north of $600k USD to cover dividend. Exudes corporate confidence regarding future. If earnings surprise shorts they will be under pressure to cover in earnest. Lucky for them that OSIR does not give $$$$ guidance. If ch47ady is correct any hint of a buyback will increase short sellers angst.
No $$$$ prediction but shorts are busy plotting how to avoid a mess. Three million shares to cover in a low float heavily insider owned stock is not for the faint of heart.
Problematic definition because just below the skin (epidermal, dermal and hypodermal or subcutaneous) layers is where one finds muscle, tendon and bone. So if full thickness includes the subcutaneous layer (which is also called fascia)....pretty fine distinction I'd say.
Probably some plastics expert out there that wants to refresh my anatomy.
And the lascivious looks and sidelong glances.
Looking in the rear view can can give a good spin to an ordinary day..if there is such a thing.
Rereading should have limited to VLUs....stasis ulcers. Many other non sanctioned uses for Grafix that OSIR should/could address with this ruling in place.
Read this quickly and am on the road so allow me some leeway if I'm not 100% on target.
Here goes: Federal court has ruled against FDA's ability to limit or forbid companies from restricting discussing off label uses as long as their is good evidence to suggest that this off label use would be efficacious. Basically if the company is being honest it becomes a free speech issue and can't be limited just because it suits the FDA's rules and regulations.
I immediately thought of DFUs and VLUs re opening the discussion and use now before ongoing studies are final. Sure seems likely that Grafix is a goodfix for these and now Osiris can openly discuss this with MDs and with patients.
This could be big for patients and Osiris shareholders.
Or has this been discussed ad infinitum and I am late to the party. Oh well....
Analysts loved the CC and will likely raise their estimates today or tomorrow. So my take is the cheap shares will prove to be a fleeting bargain.
Spend some DD here. Potential cure for Alzheimer's and very efficacious in epilepsy. Remarkable early results. Enormous unmet need with strong lobby for early approval (AARP). Market cap $70m
This could be a 50 bagger...you decide.
Read JB's posts and links on the Hub
And your point is.....? Tweets and share price don't necessarily have a positive correlation. Thank you for deigning to point that out.
Is this your advanced course offering? Can any of us here aspire to be as astute as you imagine yourself?
Foolish question, eh?